VEGFA and diabetes mellitus: This body of knowledge, accumulated over more than 15 years of pre-clinical and clinical investigation, finally led to the introduction in the clinic of nowadays consolidated treatments based on anti-VEGF monoclonal antibodies or fragments thereof, such as bevacizumab or ranibizumab, respectively, which helped to prevent diabetes-related blindness in millions of patients.